OKUR
NASDAQOnKure Therapeutics Inc.
Price$4.19+0.08 (+1.82%)
03:00 PM07:30 PM
News · 26 weeks39-90%
2026-01-252026-07-19
Mix1990d
- SEC Filings8(42%)
- Insider8(42%)
- Other3(16%)
Latest news
25 items- PROnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company's structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here. Management will provide an overview of OnKure’s strategy for de
- INSIDERPresident and CEO Saccomano Nicholas A sold $378 worth of shares (86 units at $4.40), decreasing direct ownership by 0.76% to 11,247 units (SEC Form 4) (for tax liability)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERChief Financial Officer Leverone Jason A. sold $1,332 worth of shares (303 units at $4.40), decreasing direct ownership by 2% to 18,802 units (SEC Form 4) (for tax liability)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Jansen Valerie Malyvanh4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Grey Michael G4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Carruthers R Michael4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form S-8 filed by OnKure Therapeutics Inc.S-8 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECOnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form 10-Q filed by OnKure Therapeutics Inc.10-Q - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Therapeutics Reports First Quarter 2026 Financial Results-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα pan-mutant programs into clinical development in 2027 -- $192 million cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutica
- SECSEC Form EFFECT filed by OnKure Therapeutics Inc.EFFECT - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form S-3 filed by OnKure Therapeutics Inc.S-3 - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form DEFA14A filed by OnKure Therapeutics Inc.DEFA14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- SECSEC Form DEF 14A filed by OnKure Therapeutics Inc.DEF 14A - OnKure Therapeutics, Inc. (0001637715) (Filer)
- INSIDERSEC Form 3 filed by new insider Ai Biotechnology Llc3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- SECSEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
- INSIDERSEC Form 4 filed by Saccomano Nicholas A4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Leverone Jason A.4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
OKUR FAQ
6 questionsWhere does OKUR stock trade?
OnKure Therapeutics Inc. (OKUR) is listed on NASDAQ.What sector and industry is OKUR in?
OnKure Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did OnKure Therapeutics Inc. go public?
OnKure Therapeutics Inc. (OKUR) completed its IPO in 2021.What are analysts saying about OKUR?
OnKure Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2025-04-30. Recent price targets range from $3300.00 to $3500.00.What companies are similar to OKUR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OKUR side-by-side with any of them on Quantisnow.How can I track OKUR on Quantisnow?
Quantisnow aggregates OnKure Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKUR to receive live email and push alerts on every new disclosure.